137 related articles for article (PubMed ID: 34400276)
1. The multi-specific human 17 beta-hydroxysteroid dehydrogenase type 7: Non-competitive inhibitors can target different catalyses to facilitate breast cancer treatment.
Thériault JF; Poirier D; Lin SX
J Steroid Biochem Mol Biol; 2021 Nov; 214():105963. PubMed ID: 34400276
[TBL] [Abstract][Full Text] [Related]
2. Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer.
Wang X; Gérard C; Thériault JF; Poirier D; Doillon CJ; Lin SX
J Mol Cell Biol; 2015 Dec; 7(6):568-79. PubMed ID: 25966904
[TBL] [Abstract][Full Text] [Related]
3. Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
Hilborn E; Stål O; Jansson A
Oncotarget; 2017 May; 8(18):30552-30562. PubMed ID: 28430630
[TBL] [Abstract][Full Text] [Related]
4. The dual sex hormone specificity for human reductive 17β-hydroxysteroid dehydrogenase type 7: Synergistic function in estrogen and androgen control.
Thériault JF; Lin SX
J Steroid Biochem Mol Biol; 2019 Feb; 186():61-65. PubMed ID: 30227243
[TBL] [Abstract][Full Text] [Related]
5. Substrate inhibition of 17β-HSD1 in living cells and regulation of 17β-HSD7 by 17β-HSD1 knockdown.
Han H; Thériault JF; Chen G; Lin SX
J Steroid Biochem Mol Biol; 2017 Sep; 172():36-45. PubMed ID: 28554725
[TBL] [Abstract][Full Text] [Related]
6. Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
Bellavance E; Luu-The V; Poirier D
J Med Chem; 2009 Dec; 52(23):7488-502. PubMed ID: 19772289
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Brozic P; Lanisnik Risner T; Gobec S
Curr Med Chem; 2008; 15(2):137-50. PubMed ID: 18220769
[TBL] [Abstract][Full Text] [Related]
8. Cloning and characterization of human form 2 type 7 17beta-hydroxysteroid dehydrogenase, a primarily 3beta-keto reductase and estrogen activating and androgen inactivating enzyme.
Liu H; Robert A; Luu-The V
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):173-9. PubMed ID: 15862963
[TBL] [Abstract][Full Text] [Related]
9. Multiple catalytic activities of human 17β-hydroxysteroid dehydrogenase type 7 respond differently to inhibitors.
Ferrante T; Adinolfi S; D'Arrigo G; Poirier D; Daga M; Lolli ML; Balliano G; Spyrakis F; Oliaro-Bosso S
Biochimie; 2020 Mar; 170():106-117. PubMed ID: 31887335
[TBL] [Abstract][Full Text] [Related]
10. Reductive 17beta-hydroxysteroid dehydrogenases which synthesize estradiol and inactivate dihydrotestosterone constitute major and concerted players in ER+ breast cancer cells.
Zhang CY; Wang WQ; Chen J; Lin SX
J Steroid Biochem Mol Biol; 2015 Jun; 150():24-34. PubMed ID: 25257817
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of type 1 17beta-hydroxysteroid dehydrogenase with reduced estrogenic activity: modifications of the positions 3 and 6 of estradiol.
Tremblay MR; Boivin RP; Luu-The V; Poirier D
J Enzyme Inhib Med Chem; 2005 Apr; 20(2):153-63. PubMed ID: 15968820
[TBL] [Abstract][Full Text] [Related]
12. Mutual regulations and breast cancer cell control by steroidogenic enzymes: Dual sex-hormone receptor modulation upon 17β-HSD7 inhibition.
Sang X; Han H; Li T; Lin SX
J Steroid Biochem Mol Biol; 2019 Oct; 193():105411. PubMed ID: 31207361
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of targeted 17β-hydroxysteroid dehydrogenase type 7 inhibitors.
Sancéau JY; Maltais R; Zhou M; Lin SX; Poirier D
J Steroid Biochem Mol Biol; 2024 Sep; 242():106544. PubMed ID: 38754521
[TBL] [Abstract][Full Text] [Related]
14. New development in intracrinology of breast carcinoma.
Sasano H; Suzuki T; Nakata T; Moriya T
Breast Cancer; 2006; 13(2):129-36. PubMed ID: 16755106
[TBL] [Abstract][Full Text] [Related]
15. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
Ayan D; Maltais R; Roy J; Poirier D
Mol Cancer Ther; 2012 Oct; 11(10):2096-104. PubMed ID: 22914440
[TBL] [Abstract][Full Text] [Related]
16. Human oestrogenic 17beta-hydroxysteroid dehydrogenase specificity: enzyme regulation through an NADPH-dependent substrate inhibition towards the highly specific oestrone reduction.
Gangloff A; Garneau A; Huang YW; Yang F; Lin SX
Biochem J; 2001 May; 356(Pt 1):269-76. PubMed ID: 11336660
[TBL] [Abstract][Full Text] [Related]
17. Polycyclic aromatic hydrocarbon quinone-mediated oxidation reduction cycling catalysed by a human placental 17beta-hydroxysteroid dehydrogenase.
Jarabak R; Harvey RG; Jarabak J
Arch Biochem Biophys; 1996 Mar; 327(1):174-80. PubMed ID: 8615688
[TBL] [Abstract][Full Text] [Related]
18. The selective estrogen enzyme modulators in breast cancer: a review.
Pasqualini JR
Biochim Biophys Acta; 2004 Jun; 1654(2):123-43. PubMed ID: 15172700
[TBL] [Abstract][Full Text] [Related]
19. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
20. A challenge for medicinal chemistry by the 17β-hydroxysteroid dehydrogenase superfamily: an integrated biological function and inhibition study.
Lin SX; Poirier D; Adamski J
Curr Top Med Chem; 2013; 13(10):1164-71. PubMed ID: 23647539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
